44.42
price down icon2.35%   -1.07
after-market Dopo l'orario di chiusura: 44.52 0.10 +0.23%
loading
Precedente Chiudi:
$45.49
Aprire:
$45.56
Volume 24 ore:
1.44M
Relative Volume:
0.67
Capitalizzazione di mercato:
$5.50B
Reddito:
$692.26M
Utile/perdita netta:
$-512.41M
Rapporto P/E:
-10.48
EPS:
-4.24
Flusso di cassa netto:
$-274.36M
1 W Prestazione:
-4.39%
1M Prestazione:
-10.98%
6M Prestazione:
-5.91%
1 anno Prestazione:
+39.12%
Intervallo 1D:
Value
$44.30
$45.56
Intervallo di 1 settimana:
Value
$44.30
$47.00
Portata 52W:
Value
$20.14
$53.42

Guardant Health Inc Stock (GH) Company Profile

Name
Nome
Guardant Health Inc
Name
Telefono
855-698-8887
Name
Indirizzo
3100 HANOVER STREET, PALO ALTO
Name
Dipendente
2,021
Name
Cinguettio
@guardanthealth
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
GH's Discussions on Twitter

Confronta GH con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Diagnostics & Research icon
GH
Guardant Health Inc
44.42 5.64B 692.26M -512.41M -274.36M -4.24
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
478.32 179.32B 43.21B 6.58B 6.17B 17.29
Diagnostics & Research icon
DHR
Danaher Corp
205.48 145.22B 24.01B 3.41B 4.86B 4.70
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
565.19 44.23B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
199.17 34.14B 15.50B 1.33B 2.16B 7.34
Diagnostics & Research icon
A
Agilent Technologies Inc
120.18 34.19B 6.63B 1.17B 1.19B 4.05

Guardant Health Inc Stock (GH) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-10 Iniziato Mizuho Outperform
2025-01-23 Iniziato Barclays Overweight
2024-06-28 Aggiornamento Guggenheim Neutral → Buy
2024-06-03 Ripresa Jefferies Buy
2024-04-24 Ripresa Craig Hallum Buy
2023-12-14 Iniziato Guggenheim Neutral
2023-12-13 Iniziato Wolfe Research Peer Perform
2023-11-13 Aggiornamento Raymond James Mkt Perform → Outperform
2023-09-28 Iniziato Bernstein Outperform
2023-09-27 Aggiornamento Piper Sandler Neutral → Overweight
2023-07-05 Ripresa JP Morgan Overweight
2023-05-26 Aggiornamento Citigroup Neutral → Buy
2023-05-05 Iniziato UBS Buy
2023-03-09 Downgrade Citigroup Buy → Neutral
2023-01-05 Iniziato Scotiabank Sector Outperform
2022-11-01 Downgrade Piper Sandler Overweight → Neutral
2022-10-19 Iniziato Craig Hallum Buy
2022-10-06 Iniziato Stephens Overweight
2022-08-25 Iniziato Credit Suisse Outperform
2022-06-03 Iniziato Piper Sandler Overweight
2022-04-28 Ripresa BTIG Research Buy
2022-02-24 Reiterato Canaccord Genuity Buy
2022-02-24 Reiterato Citigroup Buy
2022-02-24 Reiterato Cowen Outperform
2022-02-24 Reiterato Morgan Stanley Overweight
2022-02-24 Reiterato SVB Leerink Outperform
2022-02-24 Reiterato Stifel Buy
2022-02-24 Reiterato Wells Fargo Overweight
2021-10-15 Ripresa Cowen Outperform
2021-06-15 Iniziato Raymond James Mkt Perform
2021-06-03 Iniziato Goldman Buy
2021-05-25 Iniziato Wells Fargo Overweight
2021-01-11 Iniziato Stifel Buy
2020-09-09 Iniziato Morgan Stanley Overweight
2020-06-12 Iniziato BTIG Research Buy
2020-02-21 Iniziato Guggenheim Buy
2020-01-07 Iniziato Citigroup Buy
2019-08-07 Reiterato Canaccord Genuity Buy
2019-04-16 Iniziato Canaccord Genuity Buy
2019-04-10 Aggiornamento BofA/Merrill Neutral → Buy
2019-02-28 Reiterato BofA/Merrill Neutral
2018-10-29 Iniziato BofA/Merrill Neutral
2018-10-29 Iniziato JP Morgan Overweight
2018-10-29 Iniziato William Blair Outperform
Mostra tutto

Guardant Health Inc Borsa (GH) Ultime notizie

pulisher
Jul 25, 2025

Guardant Health Enrolls First Patient in NCI Vanguard Study for Multi-Cancer Detection Test - Insider Monkey

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Guardant Health Inc. stock priceConsistent wealth multiplication - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Minimal Residual Disease Testing Market Trends Analysis Report 2025-2030 | North America Leads in MRD Testing Market with Advanced Reimbursement Ecosystem - GlobeNewswire Inc.

Jul 25, 2025
pulisher
Jul 24, 2025

1 Healthcare Stock with Solid Fundamentals and 2 We Avoid - Yahoo Finance

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Guardant Health Inc. stockFree Stock Selection - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

10 Best Mid Cap Pharma Stocks to Buy - Insider Monkey

Jul 23, 2025
pulisher
Jul 23, 2025

Colonoscopies are no fun. These at-home colon cancer screenings offer a shortcut. - Business Insider

Jul 23, 2025
pulisher
Jul 23, 2025

Guardant Health (NASDAQ:GH investor five-year losses grow to 44% as the stock sheds US$228m this past week - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

Guardant Health Inc. Stock Analysis and ForecastFree Capital Allocation Plans - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

3 Reasons to Avoid GH and 1 Stock to Buy Instead - Yahoo Finance

Jul 23, 2025
pulisher
Jul 22, 2025

Is Guardant Health Inc. a good long term investmentFree Consultation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Cathie Wood’s ARK ETFs shift focus, buying NVIDIA and selling GUARDANT - Investing.com

Jul 22, 2025
pulisher
Jul 21, 2025

Freenome's new CEO is ready to compete in race for tests that can detect cancer earlySan Francisco Business Times - The Business Journals

Jul 21, 2025
pulisher
Jul 19, 2025

Cathie Wood's Ark Invest Offloads Meta, Loads Up On Teradyne, Caris Life Sciences - Benzinga

Jul 19, 2025
pulisher
Jul 18, 2025

Guardant Health (GH): director Tariq Musa sells $5591 in stock By Investing.com - Investing.com South Africa

Jul 18, 2025
pulisher
Jul 18, 2025

Guardant Health (GH): director Tariq Musa sells $5591 in stock - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Guardant Health Director Sells 142 Shares at $48.2 Per Share on 2025-07-17. - AInvest

Jul 18, 2025
pulisher
Jul 16, 2025

Global Liquid Biopsy Market Size Worth USD 25.24 Billion By 2032 | - openPR.com

Jul 16, 2025
pulisher
Jul 16, 2025

Lung Cancer Diagnostics Market Expansion Driven by Liquid - openPR.com

Jul 16, 2025
pulisher
Jul 16, 2025

(GH) Technical Data - news.stocktradersdaily.com

Jul 16, 2025
pulisher
Jul 15, 2025

User - FinancialContent

Jul 15, 2025
pulisher
Jul 15, 2025

Evercore ISI Keeps Their Buy Rating on Guardant Health (GH) - The Globe and Mail

Jul 15, 2025
pulisher
Jul 15, 2025

First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025 - BioSpace

Jul 15, 2025
pulisher
Jul 14, 2025

Guardant Health stock price target maintained at $60 by Evercore ISI - Investing.com Canada

Jul 14, 2025
pulisher
Jul 14, 2025

What makes Guardant Health Inc. stock price move sharplyFree Stock Portfolio Optimization - beatles.ru

Jul 14, 2025
pulisher
Jul 14, 2025

Press Release: Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025 - 富途牛牛

Jul 14, 2025
pulisher
Jul 11, 2025

Quinn Emanuel Sanctioned For Ad Case 'Misrepresentations' - Law360

Jul 11, 2025
pulisher
Jul 11, 2025

Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know - MSN

Jul 11, 2025
pulisher
Jul 11, 2025

US judge rebukes law firm Quinn Emanuel, awards $3 million sanction in Guardant case - Reuters

Jul 11, 2025
pulisher
Jul 10, 2025

East Bay company looks to bring cancer insights to rheumatoid arthritisSan Francisco Business Times - The Business Journals

Jul 10, 2025
pulisher
Jul 08, 2025

Precision Medicine Market worth $246.66 billion by 2029 with 11.1% CAGRRIVER COUNTRY - RIVER COUNTRY - NEWS CHANNEL NEBRASKA

Jul 08, 2025
pulisher
Jul 03, 2025

Guardant Health Insider Sold Shares Worth $5,087,630, According to a Recent SEC Filing - MarketScreener

Jul 03, 2025

Guardant Health Inc Azioni (GH) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
diagnostics_research WAT
$302.95
price up icon 1.50%
diagnostics_research DGX
$168.55
price down icon 1.95%
$138.90
price down icon 1.53%
diagnostics_research LH
$264.96
price down icon 1.02%
diagnostics_research MTD
$1,263.99
price up icon 0.26%
diagnostics_research A
$120.18
price down icon 0.14%
Capitalizzazione:     |  Volume (24 ore):